BioMarin Pharma (BMRN) Tops Q2 EPS by 12c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $59.75 -0.99%
Revenue Growth %: +13.2%
Financial Fact:
Provision for income taxes: -24.02M
Today's EPS Names:
CCEL, SLP, TMQ, More
Revenue Growth %: +13.2%
Financial Fact:
Provision for income taxes: -24.02M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.15, $0.12 better than the analyst estimate of $0.03. Revenue for the quarter came in at $533.8 million versus the consensus estimate of $520.35 million.
GUIDANCE:
BioMarin Pharma sees FY2022 revenue of $2.06-2.16 billion, versus the consensus of $2.11 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
- PriceSmart (PSMT) Misses Q3 EPS by 4c, Beats on Revenue
- Deutsche Bank Downgrades Simon Property Group (SPG) to Hold
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
